Assertio Holdings showed Q1 2023 net product sales increase of 18%, despite reporting a net loss due to increased expenses. Assertio's growth strategy involves expanding product range through ...

Assertio Holdings has experienced extreme price volatility, but the current price presents a buying opportunity. The company has diversified its pharmaceutical portfolio and improved its financial ...

Here is how Assertio (ASRT) and Aura Biosciences, Inc. (AURA) have performed compared to their sector so far this year.

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Assertio (ASRT) is a stock that can certainly grab the attention of many investors, ...

Assertio Holdings, Inc. is proactively engaging with investors by announcing the release date for its fourth quarter and full year 2024 financial results, which can enhance transparency and trust. The ...

Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Assertio ...

CEO Brendan O'Grady stated that "our first quarter financial results... are in line with the full-year 2025 net product sales and adjusted EBITDA expectations that were set forth during the March ...

(1) Amounts related to income recognized in the period from the lapsing of the statute of limitations for employee retention tax credits. (2) Legal settlements, net of insurance proceeds, represents ...

LAKE FOREST, Ill., January 09, 2026--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT) today announced that results of a clinical trial investigating a novel dosing ...